News & Events

• October 3, 2023
  

  C-Path Rare and Orphan Disease Conference Highlights Unprecedented Collaborations and Breakthroughs in Rare Disease Research

  TUCSON, Ariz., October. 3, 2023 — The Critical Path Institute (C-Path) held its highly anticipated Rare and Orphan Disease Conference in September, bringing together leading experts, pharmaceutical industry leaders, regulatory agencies, and patient advocates to have a dynamic dialogue about the latest advancements in rare disease research and drug development. The three-day conference, held at...
• July 18, 2023
  

  C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships

  C-Path ts activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.

• September 27, 2022
  

  Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation

  C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.

• September 15, 2022
  

  Rare Disease Workshop Highlights the Importance of Data Sharing in Drug Development

  RDCA-DAP® hosted an all-day workshop and annual meeting September 13 and 14 in Washington. The in-person and livestream event for rare disease stakeholders featured expert presentations, panel discussions, platform demonstrations, and was attended by more than 200 patients, researchers, clinicians, biopharmaceutical company representatives, regulatory reviewers and scientists.

• September 14, 2022
  

  C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases

  C-Path has announced it will serve as the convener of the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership (PPP) to benefit people across multiple rare neurodegenerative diseases, supported by a grant from the U.S. Food and Drug Administration (FDA). The Agency announced the PPP today in a press release.